Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease liver disease
Symptom C0011847|diabetes
Sentences 69
PubMedID- 24667697 The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
PubMedID- 25885947 High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels.
PubMedID- 21478462 The association of a shorter duration of diabetes with liver disease has been described before.
PubMedID- 23671610 We aim to investigate the relationships that fatty pancreas and nonalcoholic fatty liver disease (nafld) have with prediabetes and diabetes in a chinese population.
PubMedID- 20625647 Objective: to evaluate the frequency of non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (dm2) and to describe its risk factors.
PubMedID- 24625618 Er stress has been closely linked to various human diseases including inflammatory diseases, cardiovascular diseases, diabetes, and all types of human liver diseases .
PubMedID- 24485856 As for the management of diabetes in patients with liver disease, lifestyle modification plays an important role.
PubMedID- 26390278 diabetes is associated with liver disease progression and increased hepatocellular carcinoma risk, but factors associated with diabetes in patients with chronic hepatitis b virus (hbv) infection in north america are unknown.
PubMedID- 22927782 The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
PubMedID- 24952996 Established fatty liver disease is associated with diabetes, which itself induces enteric neuron damage.
PubMedID- 25790917 Conclusion: our investigations show that in fatty liver disease in combination with obesity and diabetes, the hepatocyte-protecting organelle peroxisome is altered.
PubMedID- 21435130 The aim of this case-control study is to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (t2dm) with chronic liver disease caused by hcv.
PubMedID- 22913901 Managing diabetes in patients with chronic liver disease.
PubMedID- 26573192 Objective: to investigate the effect of body mass index (bmi) on new-onset non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm).
PubMedID- 25303488 High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels.
PubMedID- 23869321 Quoted that “non-alcoholic fatty liver disease is associated with type 2 diabetes and the metabolic syndrome.” the retrospective review is done.
PubMedID- 26381272 Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.
PubMedID- 25120322 Relationship of liver stiffness and controlled attenuation parameter measured by transient elastography with diabetes mellitus in patients with chronic liver disease.
PubMedID- 24402015 Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.
PubMedID- 22787177 Despite higher susceptibility to nonalcoholic fatty liver disease in patients with type 2 diabetes, a similar alt and ast elevation was observed in a type 1 diabetes study of ly2605541 (17).
PubMedID- 23578506 Objective: to explore the liver disease spectrum in patients with type 2 diabetes (t2dm) and the risk factors of non-alcoholic fatty liver disease (nafld).
PubMedID- 24669954 Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
PubMedID- 24919218 Advancement of researches on association of non-alcoholic fatty liver disease with type 2 diabetes mellitus.
PubMedID- 21601719 Risk factors for development of liver disease for patients with bipolar disorder: diabetes (or=1.40), hiv (or=3.66), sud (or=2.68), alcohol use disorder (or=3.22) and bipolar disorder (or=2.27).
PubMedID- 23332087 This critical review of the published work aims to highlight the most recent basic and clinical data underlying the development of type 2 diabetes, in those with non-alcoholic fatty liver disease.
PubMedID- 21932714 diabetes is associated with chronic liver disease and liver cancer in the adult population of puerto rico.
PubMedID- 22024083 Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus.
PubMedID- 21664213 Due to the worldwide surge in obesity and type 2 diabetes, the increased incidence of nonalcoholic fatty liver disease (nafld) is a major concern for the public health.
PubMedID- 23991421 It has been found that among men with diabetes, the risk of chronic nonalcoholic liver disease and hcc is doubled .
PubMedID- 24912965 The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey.
PubMedID- 22156706 We examined the prevalence of advanced liver disease in people with type 2 diabetes and analysed the effectiveness of liver function tests (lfts) as a screening tool.
PubMedID- 24717062 *non-significant elixhauser comorbidity measures across the frequency groups included peripheral vascular disease, hypertension, neurological disorders, diabetes with complications, liver disease, peptic ulcer disease, acquired immunodeficiency syndrome, lymphoma, solid tumor without metastasis, coagulopathy, fluid and electrolyte disorders, anemia, and alcohol abuse.
PubMedID- 25961500 Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease.
PubMedID- 26454513 Clinically significant chronic liver disease in people with type 2 diabetes: the edinburgh type 2 diabetes study.
PubMedID- 22025861 Our study revealed that silymarin has good effect in the restoration of liver function and also established efficacy in controlling blood glucose level in diabetes patients with liver diseases.
PubMedID- 26315331 Background: liver disease in diabetes is common and is frequently the result of hepatic steatosis.
PubMedID- 20736249 In this study, we examined serum 1,5-ag levels in chronic liver disease (cld) patients with and without diabetes mellitus.
PubMedID- 24550655 Bpa has also been associated with chronic disease in humans including cardiovascular disease, diabetes, and serum markers of liver disease (14).
PubMedID- 21596453 Serum fgf21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hscrp levels independently.
PubMedID- 23433228 Previous studies reported associations of diabetes with chronic liver disease and various types of cancer .
PubMedID- 23954219 Objective: to investigate the relationship between the resistin intronic +299g/a polymorphism and nonalcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm).
PubMedID- 25841911 Majority of cases of hcc are due to chronic viral hepatitis b and c infections; however non-alcoholic fatty liver disease, associated with obesity and diabetes emerges as an important risk factor for hcc, in particular in the developed countries.
PubMedID- 26573193 Relationship of socioeconomic status and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus.
PubMedID- 25457210 Background & aims: genetic variants of patatin-like phospholipase domain-containing 3 (pnpla3) and diabetes are associated with liver disease severity, in patients with chronic hepatitis c (chc) infection.
PubMedID- 21329534 Treatment of diabetes in patients with chronic liver disease can theoretically improve survival.
PubMedID- 24587848 The association between hcv and diabetes with liver disease severity was explored by hui et al.
PubMedID- 21850244 Conclusions: elevated ggt and gpt-values as well as estimates of fatty liver disease are significantly associated with pre-diabetes and diabetes and thus very useful first indicators of a disturbed glucose metabolism.
PubMedID- 26005676 Fatty liver disease in diabetes mellitus.
PubMedID- 24071688 Objective: to observe the effect of metformin on the expression of sirt1 and ucp2 in rat liver of type 2 diabetes mellitus (t2dm) with nonalcoholic fatty liver disease (nafld), and discuss the pathogenesis of t2dm with nafld, and the treatment with and possible mechanism of metformin.
PubMedID- 23226654 Introduction: non-alcoholic fatty liver disease (nafld) is associated with type 2 diabetes (t2dm) and the metabolic syndrome, and can progress to chronic liver disease.

Page: 1 2